ArticleNature communications2025
DLFea4AMPGen de novo design of antimicrobial peptides by integrating features learned from deep learning models.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Emerging antimicrobial peptides in gastrointestinal disorders: Dual role in immunity and therapy.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Artificial intelligence driven diet-intestinal microbiota-host health integration: A four-dimensional paradigm for advancing host wellness research.iMetaOmics · 2026Review
- Natural and Synthetic AMPs from Latin America across Diversity Engineering and Applications.ACS infectious diseases · 2026Review
- MAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary-physicochemical analysis.Briefings in bioinformatics · 2026Article
- Artificial intelligence-driven discovery of bioactive peptides: Computational approaches and future perspectives.aBIOTECH · 2026Review
- Antimicrobial Peptides Against Antimicrobial-Resistant Bacteria: Focus on Machine Learning.Infection and drug resistance · 2026Review
- Antimicrobial Peptides as Cross-Seeding Modulators at the Neurodegenerative-Infectious Interface.Research (Washington, D.C.) · 2026Review
- Review
- DLFea4AMPGen de novo design of antimicrobial peptides by integrating features learned from deep learning models.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep learning models show promise in accelerating the design and optimization of antimicrobial peptides (AMPs), but current methods face challenges, such as low success rates, or large virtual library scales. In this study, we introduce DLFea4AMPGen, a bioactive peptide design strategy that leverages deep learning models to identify and extract key features associated with antimicrobial peptide activity. This approach enables the generation of peptide sequences with potential bioactivities. Using the SHapley Additive exPlanations (SHAP) method, we quantify the contribution of each amino acid in multifunctional peptides with potential antibacterial, antifungal, and antioxidant activities. Key feature fragments (KFFs) with the highest average contributions are extracted and classified into four subfamilies based on amino acid frequency. These high-frequency amino acids are systematically arranged to generate a plausible sequence subspace for candidate peptides, from which 16 representative sequences were selected for experimental validation. The results show that 75% (12/16) of the sequences exhibited at least two types of activity. Notably, D1 exhibits broad-spectrum antimicrobial activity, including efficacy against multidrug-resistant clinical pathogenic isolates both in vitro and in vivo. This proof-of-concept study underscores the potential of the DLFea4AMPGen platform for efficient design and screening of bioactive peptides, showcasing its value in AMP research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.